While there’s great promise in leveraging the power of the human immune system to fight cancer, clinicians demand greater clarity into patient selection for immuno-oncology therapies. Far too many patients receive the expensive therapies but experience no benefit, creating immense therapeutic waste.
ImaginAb addresses this challenge. Studies have shown that all current cancer immunotherapies converge on increasing the presence and activity of cytotoxic CD8 T cells. Our proprietary antibody-fragment imaging technology binds to and illuminates these critical cells, providing a whole-body image of immune response activity as well as a highly specific view of their presence at the tumor.
Following highly promising pre-clinical data, our lead immuno-oncology imaging agent IAB22M2C is currently in Phase II clinical trials.